HC Wainwright Analysts Lift Earnings Estimates for DNTH

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Research analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a report issued on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.03) per share for the quarter, up from their previous estimate of ($1.21). HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($4.07) EPS and FY2026 earnings at ($4.60) EPS.

Several other research firms have also recently weighed in on DNTH. Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen began coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Finally, Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $52.14.

Dianthus Therapeutics Trading Down 5.6 %

DNTH opened at $20.74 on Monday. Dianthus Therapeutics has a 1-year low of $18.13 and a 1-year high of $33.77. The stock has a market capitalization of $613.84 million, a price-to-earnings ratio of -8.30 and a beta of 1.82. The business has a 50 day moving average of $22.34 and a 200-day moving average of $24.70.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. MetLife Investment Management LLC increased its stake in shares of Dianthus Therapeutics by 3.1% in the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after buying an additional 433 shares in the last quarter. Invesco Ltd. raised its position in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock worth $251,000 after purchasing an additional 790 shares during the period. SG Americas Securities LLC raised its position in shares of Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after purchasing an additional 814 shares during the period. Barclays PLC raised its position in shares of Dianthus Therapeutics by 2.6% during the fourth quarter. Barclays PLC now owns 42,766 shares of the company’s stock worth $933,000 after purchasing an additional 1,082 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Dianthus Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock worth $3,641,000 after purchasing an additional 1,092 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.